Source: https://www.gsa.gov/about-us/regions/welcome-to-the-national-capital-region-11/buildings-and-facilities/project-information-nepa/fda-hq-white-oak
Timestamp: 2019-12-16 08:12:27
Document Index: 139036177

Matched Legal Cases: ['art1', 'art 2', 'art 3', 'art 4', 'art 5', 'art 6', 'art 7', 'art 8', 'art 9', 'art 10', 'art 11', 'art 12', 'art 13', 'art 1', 'art 2', 'art 1', 'art 2', 'art 3', 'art 1', 'art 2']

FDA HQ White Oak | GSA
Home/About Us/Regions/Welcome to the National Capital Region 11/Buildings and Facilities/Project Information (NEPA)/FDA HQ White Oak
St. Elizabeths Supplemental EIS
2018 FINAL ENVIRONMENTAL IMPACT STATEMENT FOR THE MASTER PLAN FOR THE CONSOLIDATION OF
THE U.S. FOOD AND DRUG ADMINISTRATION HEADQUARTERS
AT THE FEDERAL RESEARCH CENTER AT WHITE OAK, LOCATED IN SILVER SPRING, MARYLAND
The U.S. General Services Administration (GSA), in cooperation with the U.S. Food and Drug Administration (FDA), has prepared a Final Environmental Impact Statement (EIS) to analyze the potential impacts from the proposed 2018 Master Plan for the consolidation of the FDA Headquarters at the Federal Research Center (FRC) at White Oak, located in Silver Spring, Maryland. The Final EIS has been prepared in accordance with the National Environmental Policy Act (NEPA) of 1969, Council on Environmental Quality Regulations (40 CFR 1500-1508).
The purpose of the Master Plan is to provide a framework for development at the FRC to accommodate approximately 18,000 FDA employees and support staff. The Master Plan is needed to continue to support the FDA Headquarters consolidation at the FRC and provide the necessary office space to conduct the complex and comprehensive FDA reviews mandated by Congress.
The Final EIS reviews the impacts and benefits of the action alternatives and the No Action Alternative on the human environment. The alternatives evaluated can be found in Section 2.0, Alternatives Development. GSA has identified Alternative C as the Preferred Alternative. The “Preferred Alternative” is the alternative which GSA believes would best meet the purpose and need by continuing to support the FDA Headquarters’ consolidation at the FRC.
2018 FINAL FDA MP Record of Decision [PDF - 1 MB]
2018 FINAL FDA Master Plan, Part1 [PDF - 28 MB]
2018 FINAL FDA Master Plan, Part 2 [PDF - 27 MB]
2018 FINAL FDA Master Plan, Part 3 [PDF - 19 MB]
2018 FINAL FDA Master Plan, Part 4 [PDF - 5 MB]
2018 FINAL FDA Master Plan, Part 5 [PDF - 750 KB]
2018 FINAL FDA Master Plan, Part 6 [PDF - 24 MB]
2018 FINAL FDA Master Plan, Part 7 [PDF - 15 MB]
2018 FINAL FDA Master Plan, Part 8 [PDF - 23 MB]
2018 FINAL FDA Master Plan, Part 9 [PDF - 24 MB]
2018 FINAL FDA Master Plan, Part 10 [PDF - 24 MB]
2018 FINAL FDA Master Plan, Part 11 [PDF - 23 MB]
2018 FINAL FDA Master Plan, Part 12 [PDF - 24 MB]
2018 FINAL FDA Master Plan, Part 13 [PDF - 11 MB]
2018 FINAL ENVIRONMENTAL IMPACT STATEMENT, CHAPTERS 1-3 [PDF - 20 MB]
2018 FINAL ENVIRONMENTAL IMPACT STATEMENT, CHAPTERS 4-7 [PDF - 13 MB]
Final Environmental Impact Statement: Appendices A-F, Part 1 [PDF - 25 MB]
Final Environmental Impact Statement: Appendices A-F, Part 2 [PDF - 15 MB]
Final Transportation Technical Report, Appendix G [PDF - 25 MB]
Final Transportation Management Plan, Appendix H [PDF - 5 MB]
Final Traffic Technical Report Appendices , Part 1 [PDF - 2 MB]
Final Traffic Technical Report Appendices, Part 2 [PDF - 25 MB]
Final Traffic Technical Report Appendices, Part 3 [PDF - 336 KB]
FDA HQ Scoping Meeting Presentation [PDF - 5 MB]
FDA HQ Scoping Meeting Brochure [PDF - 501 KB]
2017 Federal Research Center Master Plan September 12, 2017
preliminary draft development alternatives report, Part 1 [PDF - 3 MB]
preliminary draft development alternatives report, Part 2 [PDF - 23 MB]